Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia

NCT06898983 is registered in ClinicalTrials.gov with Anhui Provincial Hospital as lead sponsor.

NCT NCT06898983
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06898983 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia
Lead sponsor
Anhui Provincial Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
July 14, 2025
Completion date
February 28, 2027
Enrollment
97 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer treatment-induced thrombocytopenia (ctit)